Evidence map›Paper›PMID 37139088›Full record

ReviewFrontiers in aging neuroscience2023

Imaging blood-brain barrier dysfunction: A state-of-the-art review from a clinical perspective.

Paulien Moyaert, Beatriz E Padrela, Catherine A Morgan, Jan Petr, Jan Versijpt, Frederik Barkhof, Michael T Jurkiewicz, Xingfeng Shao, Olujide Oyeniran, Tabitha Manson and 5 more

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Frontiers in aging neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07651787 (Neurovascular and Mitochondrial Mechanisms of Transcranial Photobiomodulation in Vascular Mild Cognitive Impairment), which is not on this map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07651787 narecruitingnot on this mapstarted 2025, after this paper: background citation

Neurovascular and Mitochondrial Mechanisms of Transcranial Photobiomodulation in Vascular Mild Cognitive Impairment

TypeinterventionalSponsorUniversity of OklahomaRan2025 to 2026Enrolled40ConditionsMild Cognitive Impairment (MCI), Amyloid PathologyArmsActive Vielight Neuro RX-Duo device -Active transcranial photobiomodulation, Sham Vielight Neuro RX-Duo device -Sham transcranial photobiomodulation
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Fully Automated Radiosynthesis of No-Carrier-Added [Journal of labelled compounds & radiopharmaceuticals · 2025
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Blood-brain barrier breakdown in brain ischemia: Insights from MRI perfusion imaging.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  18. Seeing through "brain fog": neuroimaging assessment and imaging biomarkers for cancer-related cognitive impairments.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 7 countries.

Paulien MoyaertDepartment of Medical Imaging, Ghent University Hospital, Ghent, Belgium.
Beatriz E PadrelaDepartment of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, Netherlands.
Catherine A MorganSchool of Psychology and Centre for Brain Research, The University of Auckland, Auckland, New Zealand.
Jan PetrDepartment of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, Netherlands.
Jan VersijptDepartment of Neurology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
Frederik BarkhofDepartment of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, Netherlands.
Michael T JurkiewiczDepartment of Molecular Imaging, Western University, London, ON, Canada.
Xingfeng ShaoLaboratory of FMRI Technology (LOFT), USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Olujide OyeniranLawson Health Research Institute, London, ON, Canada.
Tabitha MansonCentre for Advanced MRI, Auckland UniServices Limited, Auckland, New Zealand.
Danny J J WangLaboratory of FMRI Technology (LOFT), USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Matthias GüntherFraunhofer Institute for Digital Medicine, University of Bremen, Bremen, Germany.
Eric AchtenDepartment of Medical Imaging, Ghent University Hospital, Ghent, Belgium.
Henk J M M MutsaertsDepartment of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, Netherlands.
Udunna C AnazodoLawson Health Research Institute, London, ON, Canada.
Amsterdam Neuroscience · NLLawson Health Research Institute · CAUniversity of Southern California · USAuckland UniServices (New Zealand) · NZGhent University Hospital · BEHelmholtz-Zentrum Dresden-Rossendorf · DEMcGill University · CANational Hospital for Neurology and Neurosurgery · GBUniversitair Ziekenhuis Brussel · BEUniversity of Auckland · NZUniversity of Bremen · DEWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The blood-brain barrier (BBB) consists of specialized cells that tightly regulate the in- and outflow of molecules from the blood to brain parenchyma, protecting the brain's microenvironment. If one of the BBB components starts to fail, its dysfunction can lead to a cascade of neuroinflammatory events leading to neuronal dysfunction and degeneration. Preliminary imaging findings suggest that BBB dysfunction could serve as an early diagnostic and prognostic biomarker for a number of neurological diseases. This review aims to provide clinicians with an overview of the emerging field of BBB imaging in humans by answering three key questions: (1. Disease) In which diseases could BBB imaging be useful? (2. Device) What are currently available imaging methods for evaluating BBB integrity? And (3. Distribution) what is the potential of BBB imaging in different environments, particularly in resource limited settings? We conclude that further advances are needed, such as the validation, standardization and implementation of readily available, low-cost and non-contrast BBB imaging techniques, for BBB imaging to be a useful clinical biomarker in both resource-limited and well-resourced settings.

Indexed as

blood-brain barrier dysfunctiondiagnostic imagingmagnetic resonance imagingneurodegenerationpositron emission tomography

Identifiers

PMID37139088
PMCPMC10150073
OpenAlexW4366225276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.